#USA #datma #Beaverton #Real-World Data #Biomarker

datma Launches the Federated Biomarker Explorer

Introduction
datma, a front-runner in federated access to real-world data, has recently introduced an innovative tool known as the Federated Biomarker Explorer. This application is geared towards helping pharmaceutical teams evaluate the coverage of biomarkers across the extensive datma network of data contributors. By facilitating immediate access without the need for costly contracts or IT support, this tool has the potential to streamline the data sourcing process for pharmaceutical companies significantly.

Key Features of the Federated Biomarker Explorer
The Federated Biomarker Explorer is specifically designed to assist pharma professionals in addressing a fundamental question early in the data sourcing journey: "Does this particular dataset contain the patient populations that we require?" To achieve this, the tool provides cohort-level aggregate visibility, allowing teams to filter data by various clinical and demographic attributes. Importantly, users can do all this without involving data integration processes, procurement steps, or internal IT departments, making it highly accessible and user-friendly.

If a match is discovered between the datma network and a pharmaceutical team's target population, users have the option to link their own data for a formal overlap analysis. This critical step is conducted securely, ensuring that sensitive patient-level data does not have to be centralized or transferred, thus preserving data privacy.

Streamlining the Data Validation Process
According to Robin Edison, datma's VP of Product, pharmaceutical teams often expend significant time and resources on exploratory discussions and technical assessments before even determining the relevance of a dataset. The launch of the Federated Biomarker Explorer aims to alleviate this challenge by allowing users to swiftly ascertain the feasibility of a dataset for their specific use case.

The overarching aim of datma is to eliminate friction in real-world data collaboration by expediting the evaluation process and reducing associated risks. Instead of enduring lengthy intake processes merely to understand the contents of a dataset, users of the Federated Biomarker Explorer benefit from immediate visibility and usability from the onset of their inquiry.

Emphasis on Clarity and Accessibility
Noah Nasser, CEO of datma, emphasized the importance of clarity in data access, stating, "Access should begin with clarity. Teams shouldn’t have to invest time, budget, or legal resources simply to ascertain whether a dataset supports their objectives." This transparency is integral to fostering collaboration in the pharmaceutical sector.

For teams that identify a suitable dataset and opt to proceed, datma.FED provides the capability to perform federated analyses across both internal and external datasets while ensuring the protection of sensitive information. This feature enables teams to supplement their existing datasets with targeted real-world cohorts, effectively addressing research or market access inquiries that would otherwise fall outside the scope of their current assets. Rather than overhauling existing data structures, datma's approach focuses on filling critical gaps, ultimately presenting a faster and more efficient route to valuable insights.

Availability
As of now, the Federated Biomarker Explorer is live and available for use by pharmaceutical and life sciences teams. Those interested in learning more or requesting access to the tool can visit datma.com/trial.

About datma
datma is revolutionizing the way healthcare data is accessed and exchanged through its secure, federated ecosystem, which fosters collaboration between data custodians and consumers. Headquartered in Beaverton, Oregon, the company’s flagship offering, datma.FED, supports a marketplace for real-world healthcare data, ensuring compliance and privacy while minimizing the need for moving data or relinquishing institutional control. The platform employs advanced storage solutions, AI tools for harmonizing diverse datasets, and federated query capabilities, enhancing data utility while requiring minimal technical effort from participating organizations. It allows data custodians to generate additional revenue while retaining control, simultaneously assisting consumers in acquiring high-quality, de-identified data that enhances existing datasets and supports large-scale evidence generation. By tackling long-standing issues related to data access and privacy, datma.FED is enabling advancements in precision medicine. For further details, visit datma.com.